Can Latuda Cause Cardiac Palpitations?
Latuda (lurasidone) is not typically associated with cardiac palpitations and has a favorable cardiovascular safety profile compared to other antipsychotics, though it can cause tachycardia in approximately 14.5% of overdose cases and rare bradycardia in susceptible patients.
Cardiovascular Effects Profile
The FDA label for Latuda notably does not list palpitations as a recognized adverse effect 1. In fact, lurasidone is distinguished by having no cardiovascular adverse effects such as orthostatic hypotension or prolongation of the QTc interval at therapeutic doses 2. This makes it particularly suitable for patients with comorbid cardiovascular conditions.
What Actually Occurs
The most common cardiac-related findings with lurasidone are:
- Tachycardia: Reported in 14.5% of intentional overdose cases 3, but this is in supratherapeutic dosing scenarios
- Bradycardia: One case report documented sinus bradycardia (heart rate dropping to 48 bpm) after starting lurasidone 80 mg/day, which resolved within 5 days of discontinuation 4
- Hypertension: Seen in 6.6% of overdose cases 3
Important Context on Cardiac Safety
Lurasidone actually demonstrates protective cardiovascular properties compared to other psychotropics. A 2026 case series showed that switching patients from other antipsychotics or antidepressants to lurasidone normalized prolonged QTc intervals, suggesting it may reduce the risk of sudden cardiac death 5. The expert consensus confirms lurasidone has a favorable cardiometabolic profile 6.
Clinical Implications
If a patient reports palpitations while on Latuda:
- Consider alternative causes first - anxiety, caffeine, other medications, underlying cardiac conditions
- Check for drug interactions - lurasidone has minimal cardiac effects alone, but combinations matter
- Verify the diagnosis - obtain ECG to differentiate true arrhythmia from subjective sensation
- Monitor heart rate - both tachycardia and bradycardia are possible, though uncommon 4, 3
Overdose Considerations
In overdose situations, the FDA label specifically recommends continuous electrocardiographic monitoring for possible arrhythmias 1. However, even in a large study of 1,753 intentional overdoses, major cardiac effects occurred in only 0.7% of cases, with no deaths reported 3.
Common Pitfalls to Avoid
- Don't assume all antipsychotics have the same cardiac risk - lurasidone is notably safer than many alternatives regarding QTc prolongation 7, 5
- Don't overlook rare presentations - while uncommon, bradycardia has been documented and requires monitoring after initial administration 4
- Don't confuse subjective palpitations with objective arrhythmia - obtain ECG documentation before attributing symptoms to lurasidone
The bottom line: Palpitations are not a characteristic side effect of Latuda at therapeutic doses, and if they occur, investigate other causes before attributing them to the medication.